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Abstract
Significance: Alzheimer’s disease (AD) is an age-related progressive neurodegenerative disorder mainly af-
fecting elderly individuals. The pathology of AD is characterized by amyloid plaques (aggregates of amyloid-b
[Ab]) and neurofibrillary tangles (aggregates of tau), but the mechanisms underlying this dysfunction are still
partially unclear. Recent Advances: A growing body of evidence supports mitochondrial dysfunction as a
prominent and early, chronic oxidative stress-associated event that contributes to synaptic abnormalities and,
ultimately, selective neuronal degeneration in AD. Critical Issues: In this review, we discuss on the one hand
whether mitochondrial decline observed in brain aging is a determinant event in the onset of AD and on the
other hand the close interrelationship of this organelle with Ab and tau in the pathogenic process underlying
AD. Moreover, we summarize evidence from aging and Alzheimer models showing that the harmful trio ‘‘aging,
Ab, and tau protein’’ triggers mitochondrial dysfunction through a number of pathways, such as impairment of
oxidative phosphorylation (OXPHOS), elevation of reactive oxygen species production, and interaction with
mitochondrial proteins, contributing to the development and progression of the disease. Future Directions: The
aging process may weaken the mitochondrial OXPHOS system in a more general way over many years pro-
viding a basis for the specific and destructive effects of Ab and tau. Establishing strategies involving efforts to
protect cells at the mitochondrial level by stabilizing or restoring mitochondrial function and energy homeostasis
appears to be challenging, but very promising route on the horizon. Antioxid. Redox Signal. 16, 1456–1466.
Introduction
Aging is an inevitable biological process that results in aprogressive structural and functional decline, as well as
biochemical alterations that altogether lead to reduced ability
to adapt to environmental changes. Although aging is almost
universally conserved among all organisms, the molecular
mechanisms underlying this phenomenon still remain un-
clear. There are several theories of aging, in which free radical
(oxidative stress), DNA, or protein modifications are sug-
gested to play the major causative role (54, 72). A growing
body of evidence supports mitochondrial dysfunction as a
prominent and early, chronic oxidative stress-associated
event that contributes to synaptic abnormalities in aging and,
ultimately, increased susceptibility to age-related disorders
including Alzheimer’s disease (AD) (58). AD is the most
common neurodegenerative disorder among elderly indi-
viduals. It accounts for up to 80% of all dementia cases and
ranks as the fourth leading cause of death among those above
65 years of age. With the increasing average life span of hu-
mans, it is highly probable that the number of AD cases will
dangerously raise. The pathology of AD characterized by
abnormal formation of amyloid plaques (aggregates of amy-
loid-b [Ab]) and neurofibrillary tangles (NFT; aggregates
of tau) was shown to be accompanied by mitochondrial
dysfunction. However, the mechanisms underlying this dys-
function are poorly understood. There remain several open
questions: Is age-related oxidative stress accelerating the NFT
and Ab pathologies? Are these lesions causing oxidative stress
themselves? Or are there other mechanisms involved? Within
the past years, several mouse models have been developed
that reproduce the aging process and diverse aspects of AD.
These models help in understanding the age-related patho-
genic mechanisms that lead to mitochondrial failure in AD,
and in particular the interplay of AD-related cellular modifi-
cations within this process (17, 18).
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Mitochondrial Aging—the Beginning of the End in AD?
Mitochondria play a pivotal role in cell survival and death
by regulating both energy metabolism and apoptotic path-
ways; they contribute to many cellular functions, including
intracellular calcium homeostasis, the alteration of the cellular
reduction-oxidation (redox) potential, cell cycle regulation,
and synaptic plasticity (47). They are the ‘‘powerhouses of
cells,’’ providing energy from nutritional sources via ATP
generation, which is accomplished through oxidative phos-
phorylation (OXPHOS) (65). However, when mitochondria
fulfill their physiological function, it is as if Pandora’s box has
been opened, as this vital organelle contains potentially
harmful proteins and biochemical reaction centers; mito-
chondria are the major producers of reactive oxygen species
(ROS) at the same time being susceptible targets of ROS tox-
icity. Unstable ROS are capable of damaging many types of
mitochondrial components; this includes oxidative deterio-
ration of mitochondrial DNA (mtDNA), lipids of the mito-
chondrial membrane, and mitochondrial proteins, and it is
thought that this damage that may accumulate over time from
ROS generated from aerobic respiration may play a signifi-
cant role in aging (Fig. 1). Moreover, it was previously dem-
onstrated that nitrosative stress evoked by increased nitric
oxide synthesis also leads to protein oxidation as well as mi-
tochondrial and DNA damage, which are common mecha-
nisms occurred in elderly (13, 34, 70).
Although most mitochondrial proteins are encoded by the
nuclear genome, the mitochondrial genome encodes proteins
required for 13 polypeptide complexes of the respiratory
chain involved in ATP synthesis. Given that mtDNA exists in
the inner matrix and this is in close proximity to the inner
membrane where electrons can form unstable compounds,
mtDNA, unlike nuclear DNA (nDNA), is not protected by
histones (4) making it more vulnerable to oxidative stress and
its mutation rate is about 10-fold higher than that of nDNA,
especially in tissues with a high ATP demand like the brain
(54). These mtDNA mutations occur in genes encoding elec-
tron transport chain (ETC) subunits including NADH dehy-
drogenase, cytochrome c oxidase (COX), and ATP synthase
(83). Eventually, ROS-related mtDNA mutations can result in
the synthesis of mutant ETC proteins that, in turn, can lead to
the leakage of more electrons and increased ROS production.
This so-called ‘‘vicious cycle’’ is hypothesized to play a critical
role in the aging process according to the mitochondrial the-
ory of aging. In addition to age-associated increase in mtDNA
mutations, the amount of mtDNA also declines with age in
various human and rodent tissues (2, 68). Furthermore,
abundance of mtDNA correlates with the rate of mitochon-
drial ATP production (68), suggesting that age-related mito-
chondrial dysfunction in muscle is related to reduced mtDNA
abundance. However, age-associated change in mtDNA
abundance seems to be tissue specific, as several studies have
reported no change in mtDNA abundance with age in other
than muscular tissues in both man and mouse (20, 46).
How does the somatic mtDNA involved in aging pheno-
types contribute to AD development? As only a small fraction
of AD is caused by autosomal dominant mutations, this
comes down to the question of what is causing the prevalent
sporadic cases in the first place. Somatic mutations in mtDNA
could cause energy deficiency, increased oxidative stress, and
accumulation of Ab, which act in a vicious cycle reinforcing
mtDNA damage and oxidative stress (45). Indeed, defects in
mtDNA associated with decreased cytochrome oxidase
activity have been found in AD patients (9). Although a
similarly impaired mitochondrial function and subsequent
compensatory response have been observed in both non-
demented aged and AD subjects, no clear causative mutations
in the mtDNA have been correlated to AD; although some
variations have functional consequences, including changes
in enzymatic activity (40). Perhaps the main differences are
that, in AD brains, defects are more profound due to Ab and
tau accumulation, because of decreased compensatory re-
sponse machinery (Fig. 1).
Many investigators have developed models for studying
mitochondrial-related aging (36). Among them senescence-
accelerated mice (SAM) strains are especially useful models to
understand the mechanisms of the age-related mitochondrial
decline. Behavioral studies showed that learning and memory
deficits already started as early as 6 months and worsened
with aging in SAMP8 mice (accelerated senescence-prone 8)
(53, 77). Moreover, Omata and collaborators showed age-
related changes in cerebral energy production in the 2-month-
old SAMP8 followed by a decrease in mitochondrial function
compared with SAMR1 mice (accelerated senescence-resis-
tant 1) (51). Aging is not only connected with increased mi-
tochondrial ROS production due to ETC impairment but also
with a dysbalance of the protective antioxidant machinery
inside mitochondria. For instance, age-related changes in
levels of antioxidant enzymes, such as copper/zinc superox-
ide dismutase (Cu/Zn-SOD) and manganese SOD (Mn-SOD),
have been found in liver and cortex of SAMP8 mice when
compared with age-matched SAMR1 mice, supporting in-
creased oxidative stress as a key mechanism involved in the
aging process (37). More recently, Yew and collaborators have
shown an impairment of mitochondrial functions including a
decrease of COX activity, mitochondrial ATP content, and
mitochondrial glutathione (GSH) level at a relatively early age
in SAMP8 mice compared with SAMR1 mice (67, 78). Fur-
thermore, the biochemical consequences of aging have been
investigated using proteomic analysis in the brain of SAMP8
and SAMR1 mice at presymptomatic (5-month old) and
symptomatic (15-month old) stages (84), revealing differen-
tially expressed proteins with age in both mouse strains,
such as Cu/Zn-SOD. Besides the progressive mitochondrial
decline and increased oxidative stress, tau hyperpho-
sphorylation was also observed at an early age in the brain of
SAMP8 mice (1, 71). In addition, SAMP8 mice showed an age-
related increase in mRNA and protein levels of amyloid-b
precursor protein (APP). The cleavage product Ab was sig-
nificantly increased at 9 months in SAMP8 and amyloid pla-
ques started to form at around 16 months of age (48, 73).
Altogether, these data indicate that mitochondrial dysfunc-
tion is a highly relevant event in the aging process, which is
also known as the primary risk factor for AD and other
prevalent neurodegenerative disorders.
Age-Related Ab and Tau Effects on Mitochondria in AD
AD is a progressive, neurodegenerative disorder, charac-
terized by an age-dependent loss of memory and an impair-
ment of multiple cognitive functions. From a genetic point of
view, AD can be classified into two different forms: rare fa-
milial forms (FAD) where the disease onset is at an age below
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60 years (< 1% of the total number of AD case) and the vast
majority of sporadic AD cases where onset occurs at an age
over 60 years. Genetic studies in FAD patients have identified
autosomal dominant mutations in three different genes, en-
coding the APP (over 20 pathogenic mutations identified) and
the presenilins PS1 and PS2 (more than 130 mutations iden-
tified) (26). These mutations are directly linked to the in-
creased production of Ab from its precursor protein APP,
suggesting a direct and pathological role for Ab accumulation
in the development of AD.
Mitochondrial dysfunction has been proposed as an un-
derlying mechanism in the early stages of AD, since energy
deficiency is a fundamental characteristic feature of AD brains
(44) as well as of peripheral cells derived from AD patients
(22). Understanding the molecular pathways by which the
various pathological alterations including Ab and tau com-
promise neuronal integrity, leading to clinical symptoms, has
been a long-standing goal of AD research. The successful
development of mouse models that mimic diverse aspects of
the AD process has facilitated this effort and assisted in
FIG. 1. Aging, Ab, and tau: toxic consequence on mitochondria. The aging process may weaken the mitochondrial
OXPHOS (oxidative phosphorylation) system in a more general way by the accumulation of ROS-induced damage over
many years thereby sowing the seeds for specific and destructive effects of Ab and tau. ROS induce peroxidation of several
mitochondrial macromolecules, such as mtDNA and mitochondrial lipids, contributing to mitochondrial impairment in the
mitochondrial matrix. In AD, mitochondria were found to be a target of Ab toxicity, which may act directly or indirectly on
several proteins, leading to mitochondrial dysfunction. Indeed, Ab was found in the OMM and IMM as well as in the matrix.
The interaction of Ab with the OMM might affect the transport of nuclear-encoded mitochondrial proteins, such as subunits
of the ETC CIV, into the organelle via the TOM import machinery. Ab seems to be able to enter into the mitochondrial matrix
through TOM and TIM or could be derived from mitochondria-associated APP metabolism. The interaction of Ab with the
IMM would bring it into contact with respiratory chain complexes with the potential for myriad effects on cellular metab-
olism. It may be that Ab by these interactions affects the activity of several enzymes decreasing the ETC enzyme CIV,
reducing the amount of hydrogen that is translocated from the matrix to the intermembrane space, thus impairing the MMP.
The dysfunction of the ETC leads to a decreased CV activity and so to a lower ATP synthesis, in addition to an increased ROS
production. Interestingly, deregulation of CI is mainly tau dependent, while deregulation of CIV is Ab dependent, at both the
protein and activity level. Ab, amyloid-b; AD, Alzheimer’s disease; APP, amyloid precursor protein; CI, complex I; CII,
complex II; CIII, complex III; CIV, complex IV; CV, complex V, Cu/Zn-SOD, copper/zinc superoxide dismutase; cyt c,
cytochrome c; ETC, electron transport chain; IMM, inner mitochondrial membrane; MMP, mitochondrial membrane po-
tential; MnSOD, manganese superoxide dismutase; mtDNA, mitochondrial DNA; OMM, outer mitochondrial membrane;
ROS, reactive oxygen species; TIM, translocase of the inner membrane; TOM, translocase of the outer membrane. (To see this
illustration in color the reader is referred to the Web version of this article at www.liebertonline.com/ars).
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understanding of the age-dependent interplay of Ab and tau
on bioenergetics processes in vivo (Figs. 2 and 3).
Separate modes of Ab and tau toxicity on mitochondria
Mitochondria were found to be a target for APP toxicity as
both the full-length protein and Ab accumulate in the mito-
chondrial import channels, and both lead to mitochondrial
dysfunction (7, 42, 55, 56). Several evidences from cellular and
animal AD models indicate that Ab triggers mitochondrial
dysfunction through a number of pathways such as impair-
ment of OXPHOS, elevation of ROS production, interaction
with mitochondrial proteins, and alteration of mitochondrial
dynamics (52). Indeed, abnormal mitochondrial dynamics
have been identified in sporadic and familial AD cases (43, 76)
as well as in AD mouse model (6); a distortion probably me-
diated by altered expression of dynamin-like protein 1
(DLP1), a regulator of mitochondrial fission and distribution,
due to elevated oxidative and/or Ab-induced stress. This
modification can disturb the balance between fission and fu-
sion of mitochondria in favor of mitochondrial fission fol-
lowed by mitochondrial depletion from axons and dendrites
and, subsequently, synaptic loss.
Success in developing mouse models that mimic diverse
facets of the disease process has greatly facilitated the un-
derstanding of physiopathological mechanisms underlying
AD. Thus, in 1995, Games and collaborators established the
first APP mice model (called PDAPP) bearing the human
‘‘Indiana’’ mutation of the APP gene (V171F). They observed
the accumulation of Ab in the brain and subsequent amyloid
plaque formation as well as astrocytosis and neuritic dystro-
phy (21). Interestingly, in this model cognitive deficits, such as
spatial learning impairment, occur before the formation of Ab
plaques and increase with age (8). This phenomenon was also
observed in Tg2576 transgenic mice bearing the human
Swedish mutation of the APP gene (K670N, M671L). In fact, in
most of the APP mouse models, the cognitive impairment
begins concomitantly with Ab oligomer formation in the brain
(around 6 months of age), while neuritic amyloid deposits
become visible only between 12 and 23 months and then the
amount of deposits increases (23, 31, 35). Thus, memory def-
icits seem to directly correlate with the accumulation of in-
tracellular Ab oligomers and not with amyloid plaque
formation. Crossing APP transgenic mice with those bearing a
mutation in presenilin 1 gene enabled an earlier onset of
amyloid plaques compared with APP mice. In one of the most
FIG. 2. Age-dependent appearance of histopathological hallmarks in transgenic AD mouse model.
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aggressive models, double-transgenic APPS/L/PS1
(APPSwedish/London/PS1M141L) mice, Ab accumulation begins
very soon at 1–2 months of age while cognitive deficits and
amyloid plaque formation are already observed at 3 months
(3, 16). A stronger decrease of mitochondrial membrane po-
tential as well as ATP level was also found in these mice.
Mitochondrial dysfunctions also appear to a very early
stage in these transgenic mouse models. For example, in the
APPSw transgenic strain Tg2576, an upregulation of genes
related to mitochondrial energy metabolism and apoptosis
was observed already at 2 months of age. Alterations in
composition of the mitochondrial respiratory chain com-
plexes I and III protein subunit as well as impairment of mi-
tochondrial respiration were detected around 6 months, when
soluble Ab accumulated in the brain without plaque forma-
tion (10, 23, 59). To test the hypothesis that oxidative stress can
underlie the deleterious effects of PS mutations, Schuessel
and collaborators analyzed lipid peroxidation products (4-
hydroxynonenal [HNE] and malondialdehyde) and antioxi-
dant defense mechanisms in brain tissue and ROS levels in
splenic lymphocytes from transgenic mice bearing the human
PS1 M146L mutation (PS1M146L) compared with those from
mice transgenic for wild-type human PS1 (PS1wt) and non-
transgenic littermate control mice (66). In brain tissue,
HNE levels were increased only in aged (19–22 months)
PS1M146L transgenic animals compared with PS1wt mice
and not in young (3–4 months) or middle-aged mice (13–15
months). Similarly, in splenic lymphocytes expressing the
transgenic PS1 proteins, mitochondrial and cytosolic ROS
levels were significantly elevated compared with controls
only in cells from aged PS1M146L animals. Antioxidant
defense mechanisms (activities of antioxidant enzymes in-
cluding Cu/Zn-SOD, GSH peroxidase, and GSH reductase)
as well as susceptibility to oxidative stress in vitro were
unaltered. In summary, these results demonstrate that the
PS1M146L mutation increases mitochondrial ROS formation
and oxidative damage selectively in aged mice. Consistent
with this observation, in Swedish amyloid precursor protein
(APPSw)/PS2 double-transgenic mice, mitochondrial im-
pairment was first detected at 8 months of age, before am-
yloid plaque deposition, but after soluble Ab accumulation
(60, 61). Taken together, these findings are consistent with
the recently proposed hypothesis of the age-related Ab
toxicity cascade that suggests that the most toxic Ab species
that cause majority of molecular and biochemical abnor-
malities are in fact intracellular soluble oligomeric
FIG. 3. Age-dependent mitochondrial dysfunction in senescence-accelerated and transgenic AD mouse models. (Star:
start of the experiments).
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aggregates rather than the extracellular, insoluble plaques
that may comprise the form of cellular defense against tox-
icity of oligomers (19). Interestingly, human amylin that
aggregates in type 2 diabetic pancreas and shares with Ab
its amyloidogenic properties also causes an impaired com-
plex IV activity, whereas nonamyloidogenic rat amylin did
not (39).
How does tau interfere with mitochondrial function? In its
hyperphosphorylated form, tau, which forms the NFTs, the
second hallmark lesion in AD, has been shown to block mi-
tochondrial transport, which results in energy deprivation
and oxidative stress at the synapse and, hence, neurodegen-
eration (27, 33, 57). Till now, no mutations in microtubule-
associated protein tau (MAPT) coding genes have been
detected in relation to familial forms of AD. However, in
familial frontotemporal dementia (FTD) with parkinsonism,
mutations in the MAPT gene were identified on chromosome
17. This was the basis for creating a robust mouse model for
tau pathology in 2001. These P301L tau–expressing pR5 mice
(longest four-repeat 4R2N) show an accumulation of tau as
soon as 3 months of age and develop NFTs around 6 months
of age (24). A mass spectrometric analysis of the brain
proteins from these mice revealed mainly a deregulation of
mitochondrial respiratory chain complex components (in-
cluding complex V), antioxidant enzymes, and synaptic
protein space (11). The reduction in mitochondrial complex V
levels in the P301L tau mice that was revealed using pro-
teomics was also confirmed as decreased in human P301L
FTDP-17 (FTD with parkinsonism linked to chromosome 17)
brains. The functional analysis demonstrated age-related
mitochondrial dysfunction, together with reduced NADH-
ubiquinone oxidoreductase (complex I) activity as well as
age-related impaired mitochondrial respiration and ATP
synthesis in pR5 mice model. Mitochondrial dysfunction was
also associated with higher levels of ROS in aged transgenic
mice. Increased tau pathology resulted in modification of
lipid peroxidation levels and the upregulation of antioxidant
enzymes in response to oxidative stress (11). Thus, this
evidence demonstrated for the first time that not only Ab but
also tau pathology leads to metabolic impairment and
oxidative stress by distinct mechanisms from that caused by
Ab in AD.
Synergistic modes of Ab and tau toxicity
on mitochondria
Although Ab and tau pathologies are both known hall-
marks of AD, the mechanisms underlying the interplay be-
tween plaques and NFTs (or Ab and tau, respectively) have
remained unresolved. However, a close relationship between
mitochondrial impairment and Ab on the one hand and tau
on the other hand has been already established. How do both
AD features relate to each other? Is it possible that these two
molecules synergistically affect mitochondrial integrity?
Several studies suggest that Ab aggregates and hyperpho-
sphorylated tau may block the mitochondrial carriage to the
synapse leading to energy deficiency and neurodegeneration
(28). Moreover, the enhanced tau levels may inhibit the
transport of APP into axons and dendrites, which suggests a
direct link between tau and APP in axonal failure (14, 69).
Remarkably, intracerebral Ab injections amplify a preexisting
tau pathology in several transgenic mouse models (5, 25, 29),
whereas lack of tau abrogates Ab toxicity (32, 33). Our find-
ings indicate that in tau transgenic pR5 mice, mitochondria
display an enhanced vulnerability toward an Ab insult in vitro
(12, 15, 16), suggesting a synergistic action of tau and Ab
pathology on this organelle (Figs. 2 and 3). The Ab caused a
significant reduction of mitochondrial membrane potential in
cerebral cells from pR5 mice (11). Furthermore, incubation of
isolated mitochondria from pR5 mice with either oligomeric
or fibrillar Ab species resulted in an impairment of the mito-
chondrial membrane potential and respiration. Interestingly,
aging particularly increased the sensitivity of mitochondria to
oligomeric Ab insult compared with that of fibrillar Ab (15).
This suggests that while both oligomeric and fibrillar Ab
species are toxic, they exert different degrees of toxicity.
Crossing P301L mutant tau transgenic JNPL3 mice (shortest
four-repeat [4R0N] tau together with the P301L mutation)
with APPSw transgenic Tg2576 mice revealed the presence of
NFT pathology in spinal cord and pons already at 3 months of
age (38). Ab plaques were detected at the age of 6 months and
had the same morphology and distribution than in the 1-year-
old Tg2576 mice. Taken together, these studies illustrate the
existence of a complex interplay between the two key proteins
in AD.
Additionally, in recent years triple-transgenic mouse models
have been established that combine Ab and tau pathologies (Figs.
2 and 3). In these models the contribution of both AD-related
proteins on the mitochondrial respiratory machinery and energy
homeostasis has been investigated in vivo. Indeed, our group
demonstrated a mitochondrial dysfunction in a novel triple-
transgenic mouse model (pR5/APPSw/PS2 N141I)—tripleAD
mice—using proteomics followed by functional validation
(60). Particularly, deregulation of activity of complex I was
found to be tau dependent, whereas deregulation of complex
IV was Ab dependent, in 10-month-old tripleAD mice. The
convergent effects of Ab and tau led already at the age of
8 months to a depolarization of mitochondrial membrane
potential in tripleAD mice. Additionally, we found that age-
related oxidative stress also plays a significant part in the
deleterious vicious cycle by exaggerating Ab- and tau-
induced disturbances in the respiratory system and ATP
synthesis, finally leading to synaptic failure.
Our data complement those obtained in another triple-
transgenic mouse model 3xTg-AD (P301Ltau/APPSw/PS1
M146L) (50). In these studies, mitochondrial dysfunction was
evidenced by an age-related decrease in the activity of regu-
latory enzymes of OXPHOS such as COX, or of the Krebs cycle
such as pyruvate dehydrogenase, analyzing 3xTg-AD mice
aged from 3 to 12 months (82). Besides, these mice also ex-
hibited increased oxidative stress and lipid peroxidation.
Most of the effects on mitochondria were seen at the age of 9
months, whereas mitochondrial respiration was significantly
decreased at 12 months of age. Importantly, mitochondrial
bioenergetics deficits were found to precede the development
of AD pathology in the 3xTg-AD mice. Figure 4 nicely shows
that AD-specific changes including cognitive impairments,
Ab accumulation, Ab plaques, and mitochondrial dysfunction
seem to occur at an earlier onset from single, double up to
triple AD transgenic mice models. Together, our studies
highlight the key role of mitochondria in AD pathogenesis
and consolidate the notion that a synergistic effect of tau and
Ab enhances the pathological weakening of mitochondria at
an early stage of AD.
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Ab-Binding Alcohol Dehydrogenase: A New Lead
to Decode the Mechanisms of Ab-Induced
Mitochondrial Dysfunction
A few years ago, Yan and collaborators showed that the Ab
peptide can directly bind a mitochondrial enzyme called Ab-
binding alcohol dehydrogenase (ABAD) that is overexpressed
in the brains of Alzheimer’s patients and AD mouse models
(79). The interaction of Ab with this enzyme exacerbates mi-
tochondrial dysfunction induced by Ab (decrease of mito-
chondrial complex IV activity, diminution of O2 consumption,
and increase of ROS), as shown in double-transgenic mice
overexpressing mutant APP and ABAD (81). Furthermore,
these mice presented an earlier onset of cognitive impairment
and histopathological changes when compared with APP
mice, suggesting that the Ab–ABAD interaction is an impor-
tant mechanism underlying Ab toxicity. The Ab–ABAD
complex could have a direct effect on the ETC because ABAD
was found to be one of three proteins that comprise the fully
functional mammalian mitochondrial RNAse P (63), a func-
tion that may not require dehydrogenase activity and that
links ABAD directly to the production of mitochondrial ETC
proteins and ROS generation.
Recently, it has been shown that inhibition of Ab–ABAD
interaction by a decoy peptide can restore mitochondrial
deficits and improve neuronal and cognitive function (81).
Our findings, using SH-SY5Y neuroblastoma cells treated
with Ab1-42, a cellular model of AD, seem to confirm these
observations (Lim et al., unpublished observations). We em-
ployed a novel small ABAD-specific inhibitor to investigate
the role of this enzyme in Ab toxicity. The inhibitor signifi-
cantly improved metabolic functions impaired by Ab, and
specifically reduced Ab-induced oxidative stress and cell
death. Furthermore, we have shown previously that the
production of estradiol, a well-known neuroprotective neu-
rosteroid and ABAD substrate, is increased after 24 h in the
presence of a ‘‘nontoxic’’ concentration of Ab and is de-
creased when using a toxic concentration of this peptide (64),
suggesting that Ab is able to modulate (directly or indirectly)
neurosteroid levels. Accordingly, new findings from our
group demonstrate that the levels of estradiol in the cytosol
and in mitochondria can differently be influenced by Ab
peptide (500 nM, 5 days of treatment) (Fig. 5A, B). We ob-
served that cytosolic estradiol is reduced in the presence of
Ab, but at the same time mitochondrial estradiol load was
significantly increased. We suggest that this increase is due
to an Ab-induced decrease of ABAD activity, thus limiting
the conversion of estradiol in estrone within mitochondria
(Fig. 5C). Inhibition of ABAD activity by Ab peptide was
already demonstrated by Yan and collaborators (80) using
17b-estradiol as substrate of the enzyme. One mechanism
that could explain this inhibition is the fact that Ab–ABAD
interaction changes the conformation of the enzyme, avoid-
ing the binding of the cofactor NAD + , and this reduces the
metabolic activity of ABAD (41). However, the total amount
of estradiol is about 500-fold higher than in the mitochon-
drial fraction. Even if Ab induced an increase in estradiol
within mitochondria, the reduction of total estradiol level by
other enzymes of the complex steroidogenic pathway may
therefore be more relevant for cellular dysfunction. Besides,
FIG. 4. Age-dependent onset of AD-associated pathological changes in different AD mouse models (age in months). In
both triple Tg mouse models [TripleAD, (60); 3xTgAD, (50–82)] an earlier onset in the appearance of AD-related changes in the
brain can be detected when compared with double transgenic [APPSw/PS2 (60, 61)] and to mice bearing only APP mutations
[APPSw, (24)], suggesting again a synergistic effect of Ab and tau in the pathogenesis of AD. Age of the mice is given in
months. APPSw, APP Swedish transgenic mice; APPSw/PS2, APP Swedish/presenilin 2 transgenic mice; tripleAD, APP
Swedish/presenilin 2/P301L tau transgenic mice; 3xTgAD, APP Swedish/presenilin 1/P301L tau transgenic mice. (To see
this illustration in color the reader is referred to the Web version of this article at www.liebertonline.com/ars).
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it was also speculated that estradiol exhibits a ‘‘prooxidant
effect’’ in the presence of ongoing oxidative stress (49).
Thereby, estradiol is hydroxylated to catecholestrogens that
can enter a redox cycle generating superoxide radicals,
leading to a continuous formation of ROS that amplifies
oxidative stress.
Thus, inhibition of the Ab–ABAD interaction seems to be
an interesting therapeutic target to block or prevent Ab-
induced mitochondrial toxicity because it could normalize the
imbalance between ROS and estradiol levels in mitochondria
and thereby help in improving mitochondrial and neuronal
function.
Conclusion
We discuss here the recent findings regarding the possible
shared mechanisms involving mitochondrial decline driven
by brain aging and the close interrelationship of this organelle
with the two main pathological features in the pathogenic
process underlying AD.
According to the mitochondrial aging theory, ROS-induced
damage and mtDNA mutations accumulate over time in-
ducing ETC impairment and weaken mitochondria function
in a rather unspecific way; thus, laying the ground for the two
common hallmarks of AD, plaques and NFTs, or Ab and tau,
respectively, which destruct independently as well as syner-
gistically this vital organelle via specific mode of actions on
complexes I and IV.
Given the complexities of AD, the key role of mitochondrial
dysfunction in the early pathogenic pathways by which Ab
leads to neuronal dysfunction in AD is particularly chal-
lenging with respect to establishing therapeutic treatments.
Besides the modulation and/or removal of both Ab and tau
pathology, strategies involving efforts to protect cells at the
mitochondrial level by stabilizing or restoring mitochondrial
function or by interfering with energy metabolism appear to
be promising. Transgenic AD mice, and particularly triple-
transgenic models that combine both pathologies in an age-
dependent manner (Fig. 4), are valuable tools in monitoring
therapeutic interventions at the mitochondrial level. Even-
tually, this may lead to therapies that prevent the progression
of the age-related mitochondrial decline thereby reducing the
vulnerability to Ab and/or tau at an early stage of the disease.
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APP¼ amyloid precursor protein
APPSw¼ Swedish amyloid precursor protein
APPwt¼wild-type amyloid precursor protein
COX¼ cytochrome c oxidase
DLP1¼dynamin-like protein 1
















ROS¼ reactive oxygen species
SAM¼ senescence-accelerated mice
SOD¼ superoxide dismutase
TIM¼ translocase of the inner membrane
TOM¼ translocase of the outer membrane
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